BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20418232)

  • 1. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type.
    Clarke BA; Gilks CB
    J Clin Pathol; 2010 May; 63(5):410-5. PubMed ID: 20418232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
    Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
    Bartosch C; Manuel Lopes J; Oliva E
    Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
    McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
    Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histologic diagnosis of endometrial cancer].
    Kaku T; Kawano Y; Hagiwara T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():309-12. PubMed ID: 15535257
    [No Abstract]   [Full Text] [Related]  

  • 8. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
    Zhang L; Liu Y; Hao S; Woda BA; Lu D
    Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
    Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for distinguishing low-grade endometrioid and serous carcinomas of endometrium.
    Garg K; Soslow RA
    Adv Anat Pathol; 2012 Jan; 19(1):1-10. PubMed ID: 22156830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
    Schlosshauer PW; Ellenson LH; Soslow RA
    Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of immunohistochemistry in differential diagnosis of endometrial carcinoma].
    Wu HW; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):784-8. PubMed ID: 23302346
    [No Abstract]   [Full Text] [Related]  

  • 14. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
    Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
    Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.
    Pothuri B; Ramondetta L; Eifel P; Deavers MT; Wilton A; Alektiar K; Barakat R; Soslow RA
    Gynecol Oncol; 2006 Dec; 103(3):948-51. PubMed ID: 16870239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
    Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
    Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
    Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
    Quddus MR; Sung CJ; Zhang C; Lawrence WD
    Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.